title: Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma.
abstract: Microsatellite instability (MSI) has been reported in various tumors, with colon cancer as the prototype. However, little is known about MSI in Barrett esophagus (BE)-associated adenocarcinoma. Thus, the aim of this study was to compare the clinicopathologic and molecular features of BE-associated adenocarcinomas with and without MSI. The study cohort consisted of 76 patients with BE-associated adenocarcinomas (66 male, 10 female), with a mean age of 65.1 years. Immunohistochemistry (IHC) for MLH1, MSH2, MSH6, PMS2, and CD3 and in situ hybridization for Epstein-Barr virus-encoded RNA were performed. MLH1 and PMS2 expression was lost by IHC in 5 cases (6.6%); of these, 5 showed high-level MSI (MSI-H) by polymerase chain reaction assay, and 4 showed hMLH1 promoter methylation. Histologically, tumors with MSI-H were heterogenous and included conventional adenocarcinomas with tumor-infiltrating lymphocytes (n=1), medullary carcinoma (n=2), signet ring cells (n=1), and signet ring cell and mucinous components (n=1). Compared with tumors negative for MSI by IHC, BE-associated adenocarcinomas with MSI-H were associated with older patient age (P=0.0060), lymphovascular invasion (P=0.027), and significantly larger numbers of tumor-infiltrating lymphocytes (P<0.0001). However, there was no statistical difference in overall survival between the 2 groups (P=0.285). In conclusion, MSI-H is uncommon in BE-associated adenocarcinomas, but is associated with clinicopathologic features fairly similar to sporadic microsatellite unstable colorectal cancers. Given the growing evidence that indicates lack of benefits from adjuvant therapy with fluorouracil in the colonic counterpart, it may be important to identify MSI-H in BE-associated adenocarcinomas.
authors.affiliation: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
authors.forename: Alton B
authors.initials: AB
authors.lastname: Farris
authors.forename: Elizabeth G
authors.initials: EG
authors.lastname: Demicco
authors.forename: Long Phe
authors.initials: LP
authors.lastname: Le
authors.forename: Karin E
authors.initials: KE
authors.lastname: Finberg
authors.forename: Julie
authors.initials: J
authors.lastname: Miller
authors.forename: Rajni
authors.initials: R
authors.lastname: Mandal
authors.forename: Junya
authors.initials: J
authors.lastname: Fukuoka
authors.forename: Cynthia
authors.initials: C
authors.lastname: Cohen
authors.forename: Henning A
authors.initials: HA
authors.lastname: Gaissert
authors.forename: Lawrence R
authors.initials: LR
authors.lastname: Zukerberg
authors.forename: Gregory Y
authors.initials: GY
authors.lastname: Lauwers
authors.forename: A John
authors.initials: AJ
authors.lastname: Iafrate
authors.forename: Mari
authors.initials: M
authors.lastname: Mino-Kenudson
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D000368:Aged; D001471:Barrett Esophagus / Q000150:complications / Q000235:genetics / Q000473:pathology*; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D016246:Lymphocytes, Tumor-Infiltrating / Q000473:pathology; D008297:Male; D053842:Microsatellite Instability; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction